```
=> d his

     (FILE 'HOME' ENTERED AT 10:26:06 ON 14 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:26:54 ON 14 NOV 2007
L1                STRUCTURE UPLOADED
L2              1 S L1
L3              4 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:27:31 ON 14 NOV 2007
L4              1 S L3

=> d que l4 stat
L1                STRUCTURE
```




```
G1 Me,Et,n-Pr,i-Pr,n-Bu,[@1]


Structure attributes must be viewed using STN Express query preparation.
L3              4 SEA FILE=REGISTRY SSS FUL L1
L4              1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3


=> d bib abs hitstr
```

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:991360 CAPLUS
DN 140:42170
TI Preparation of arylazopyrazoles as thrombopoietin mimetics
IN Heerding, Dirk A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103686	A1	20031218	WO 2003-US17837	20030606
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003248630	A1	20031222	AU 2003-248630	20030606
	EP 1556059	A1	20050727	EP 2003-757372	20030606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006501164	T	20060112	JP 2004-510805	20030606
	US 2005234020	A1	20051020	US 2004-516988	20041206
PRAI	US 2002-386694P	P	20020606		
	US 2003-463241P	P	20030416		
	WO 2003-US17837	W	20030606		

OS MARPAT 140:42170
GI



AB Title compds. I [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHO, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)H(OH), heterocyclylidenemethyl; m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as thrombopoietin mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give 2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give 1 [R =

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-Me2CC6H4, R1-R3 = H, R4 = Me, R5 = cyclohexyl, m = 0].
IT 634586-04-2P 634586-07-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylazopyrazoles as thrombopoietin mimetics)
RN 634586-04-2 CAPLUS
CN Hydrazine, (3-ethylcyclopentyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 634586-03-1
CMF C7 H16 N2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 634586-07-5 CAPLUS
CN Hydrazine, [3-(1,1-dimethylpropyl)cyclopentyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 634586-06-4
CMF C10 H22 N2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:28:45 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 NOV 2007  HIGHEST RN 953361-13-2
DICTIONARY FILE UPDATES:  13 NOV 2007  HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d 13 1-4 ide can
```

L3 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-07-5 REGISTRY
ED Entered STN: 06 Jan 2004
CN Hydrazine, [3-(1,1-dimethylpropyl)cyclopentyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
MF C10 H22 N2 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 634586-06-4
CMF C10 H22 N2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L3 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-06-4 REGISTRY
ED Entered STN: 06 Jan 2004
CN Hydrazine, [3-(1,1-dimethylpropyl)cyclopentyl]- (CA INDEX NAME)
MF C10 H22 N2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-04-2 REGISTRY
ED Entered STN: 06 Jan 2004
CN Hydrazine, (3-ethylcyclopentyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
MF C7 H16 N2 . C2 H F3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 634586-03-1
CMF C7 H16 N2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L3 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-03-1 REGISTRY
ED Entered STN: 06 Jan 2004
CN Hydrazine, (3-ethylcyclopentyl)- (CA INDEX NAME)
MF C7 H16 N2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> => d que l7 stat
L5 STR



G1 [@1], [@2]
G2 H, Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu
G3 Me, Et, n-Pr, i-Pr, n-Bu, [@3]

Structure attributes must be viewed using STN Express query preparation.
L7 6 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 86116 ITERATIONS 6 ANSWERS

L7 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-08-6 REGISTRY
ED Entered STN: 06 Jan 2004
CN 3H-Pyrazol-3-one, 2-[3-(1,1-dimethylpropyl)cyclopentyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)
MF C14 H24 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L7 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-05-3 REGISTRY
ED Entered STN: 06 Jan 2004
CN 3H-Pyrazol-3-one, 2-(3-ethylcyclopentyl)-2,4-dihydro-5-methyl- (CA INDEX NAME)
MF C11 H18 N2 O
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L7 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634585-99-2 REGISTRY
ED Entered STN: 06 Jan 2004
CN 3H-Pyrazol-3-one, 2-[trans-4-(1,1-dimethylethyl)cyclohexyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)
FS STEREOSEARCH
MF C14 H24 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L7 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634585-98-1 REGISTRY
ED Entered STN: 06 Jan 2004
CN 3H-Pyrazol-3-one, 2-[cis-4-(1,1-dimethylethyl)cyclohexyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)
FS STEREOSEARCH
MF C14 H24 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L7 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 553671-91-3 REGISTRY
ED Entered STN: 24 Jul 2003
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-(4-methylcyclohexyl)- (CA INDEX NAME)
MF C11 H18 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:85373

L7 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 36210-76-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)
OTHER NAMES:
CN 1-Cyclohexyl-3-methyl-2-pyrazolin-5-one
MF C10 H16 N2 O
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL, USPATOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:142553

REFERENCE 2: 146:33020

REFERENCE 3: 145:124560

REFERENCE 4: 144:128971

REFERENCE 5: 142:74598

REFERENCE 6: 140:192190

REFERENCE 7: 140:42170

REFERENCE 8: 139:286349

REFERENCE 9: 139:261293

REFERENCE 10: 139:85373

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 10:32:03 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 13 Nov 2007  (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s 17
L8          17 L7

=> d 1-17 bib abs hitstr
```

L8 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1252494 CAPLUS
DN 146:33020
TI Pharmaceutical comprising pyrazolone derivative
IN Mutai, Mamoru; Ohyama, Naoki; Ishii, Shunichiro; Morita, Miyuki; Inagaki, Kiyoharu
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 29pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006126625	A1	20061130	WO 2006-JP310425	20060525

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 2005-152274 A 20050525

AB Disclosed is a pharmaceutical which is intended to be administered in such a form that can reduce a renal disorder exacerbated upon the administration of a pyrazolone derivative and an antibiotic in combination. A cerebral protective agent for use in a patient who receives the administration with an antibiotic, comprising a pyrazolone derivative (e.g., 3-methyl-1-phenyl-2-pyrazolin-5-one) or a physiol. acceptable salt thereof or a hydrate or solvate of the derivative or salt as an active ingredient, the pyrazolone derivative or physiol. acceptable salt thereof or the hydrate or solvate of the derivative or salt being administered subsequent to the administration of the antibiotic.
IT 36210-76-1, 1-Cyclohexyl-3-methyl-2-pyrazolin-5-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical comprising pyrazolone derivative)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1190060 CAPLUS
DN 146:142553
TI Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5-pyrazolone with an intramolecular base
AU Nakagawa, Hidehiko; Ohyama, Ryo; Kimata, Ayako; Suzuki, Takayoshi; Miyata, Naoki
CS Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, 467-8603, Japan
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5939-5942
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 146:142553
GI



I

AB Pyrazolones such as I are prepared as analogs of edaravone; the oxidation potentials of the pyrazolones are determined as well as the hydroxyl radical scavenging activities for some of the compds. I is more effective in a hydroxyl radical scavenging assay than edaravone, with an IC50 value of 0.018 mM as compared to edavarone's IC50 value of 0.25 mM. The hydroxyl radical scavenging activities of some of the pyrazolones are correlated to their oxidation potentials. The energies of protonation and the calculated pKa values are determined by calcns. for selected pyrazolones.
IT 36210-76-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of pyrazolones as edaravone analogs for potential use as antioxidants and their oxidation potentials)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:655838 CAPLUS
DN 145:124560
TI Preparation of pyrazolones as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
IN Balestra, Michael; Bunting, Heather; Chen, Deborah; Egle, Ian; Forst, Janet; Frey, Jennifer; Isaac, Methvin; Ma, Fupeng; Nugiel, David; Slassi, Abdelmalik; Steelman, Gary; Sun, Guang-Ri; Sundar, Babu; Ukkiramapandian, Radhakrishnan; Urbanek, Rebecca A.; Walsh, Sally
PA Astrazeneca AB, Swed.; NPS Pharmaceuticals, Inc.
SO PCT Int. Appl., 332 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006071730	A1	20060706	WO 2005-US46606	20051222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005322173	A1	20060706	AU 2005-322173	20051222
CA 2591003	A1	20060706	CA 2005-2591003	20051222
EP 1833800	A1	20070919	EP 2005-855204	20051222

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

IN 2007DN04444	A	20070824	IN 2007-DN4444	20070611

PRAI US 2004-638369P P 20041227
WO 2005-US46606 W 20051222
OS MARPAT 145:124560
GI



I



II

AB The title compds. I [X = F, Cl, Br, I, CN, etc.; Q = C, O, S, and N; ring containing Q = 5-7 membered ring which is optionally fused with one or more

L8 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
5-7 membered rings; R1 = alkyl, aryl, heteroaryl, etc.; R2 = H, alkyl, alkenyl, and alkynyl; R3, R4 = H, alkyl, aryl, etc.; R5, R6 = H, OH, F, Cl, Br, I, etc.; n = 1-6; with provisos], useful in the treatment or prevention of neurol. and psychiatric disorders assocd. with glutamate dysfunction, were prepd. Thus, reacting 5-(bromomethyl)-4-chloro-1-methyl-2-phenylpyrazolidin-3-one with 1-(4-chlorophenyl)piperazine.2HCl afforded 91% II. Compds. I are active in assays of mGluR function with EC50 of less than about 10 μM. Pharmaceutical compns. contg. the compds. I are disclosed.
IT 36210-76-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolones as metabotropic glutamate receptor agonists for the treatment of neurol. and psychiatric disorders)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:32180 CAPLUS
DN 144:128971
TI Preparation of thienopyrazole derivatives as PDE7 inhibitors
IN Inoue, Hidekazu; Murafuji, Hidenobu; Hayashi, Yasuhiro
PA Daiichi Asubio Pharma Co., Ltd., Japan
SO PCT Int. Appl., 329 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006004040	A1	20060112	WO 2005-JP12208	20050701
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005258410	A1	20060112	AU 2005-258410	20050701
	CA 2569530	A1	20060112	CA 2005-2569530	20050701
	EP 1775298	A1	20070418	EP 2005-765241	20050701
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1976938	A	20070606	CN 2005-80021480	20050701
	KR 2007039505	A	20070412	KR 2006-727869	20061229
	IN 2007KN00332	A	20070706	IN 2007-KN332	20070129
PRAI	JP 2004-195836	A	20040701		
	WO 2005-JP12208	W	20050701		

OS MARPAT 144:128971
GI



I

AB The title compds. I [R1 = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted heterocycloalkyl; R2 = H, (un)substituted alkyl; R3 = H, (un)substituted alkyl, halo; R4 = (un)substituted aryl, (un)substituted heteroaryl, CO2R7, etc.; R7 = H, (un)substituted alkyl] are prepared. I have selective inhibitory activity against PDE7 and thus heighten the intracellular cAMP level to inhibit the activation of T cells. I are hence useful in the prevention and treatment of various allergic diseases and inflammatory and immunol. diseases. Thus, N-benzyl-1-cyclohexyl-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide was prepared in a multistep process from cyclohexylhydrazine HCl salt and Me

L8 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1127384 CAPLUS
DN 142:74598
TI Preparation of (pyridinyl)pyrazolopyrimidinone derivatives as PDE 7 inhibitors
IN Inoue, Hidekazu; Murafuji, Hidenobu; Hayashi, Yasuharu
PA Daiichi Suntory Pharma Co., Ltd., Japan; Daiichi Suntory Biomedical Research Co., Ltd.
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004111054	A1	20041223	WO 2004-JP8643	20040611
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006219373	A	20060824	JP 2003-170094	20030613
	EP 1636235	A1	20060322	EP 2004-736704	20040611
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2006128728	A1	20060615	US 2005-560386	20051213
PRAI	JP 2003-170094	A	20030613		
	WO 2004-JP8643	W	20040611		

OS MARPAT 142:74598
GI



I



II



III

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
acetoacetate. Compds. of this invention showed IC50 values of 0.004 μM to 0.009 μM against phosphodiesterase 7.
IT 36210-76-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thienopyrazole derivs. as PDE7 inhibitors)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
AB Title compds. represented by the formula I & II [wherein R1 = (un)substituted cycloalkyl or CMe3; R2 = H or alkyl; R3 = amino, COR7, SO0-2R8; R4 = H or (un)substituted alkoxy; R7 = alkoxy or amino; R8 = H, halo, amino, (un)substituted alkyl, aryl; and pharmaceutically acceptable salts or solvates thereof] were prepared as PDE 7 inhibitors. For example, III was given in a multi-step synthesis starting from Me 2-methoxy-6-(4-methylphenylthio)pyridine-3-carboxylate. III showed inhibition of PDE 7 inhibitors with IC50 values of 0.0026 μM. Thus, I & II and their pharmaceutical compns. are useful for the treatment of various kinds of disease, such as allergic disease, inflammatory disease or immunol. disease (no data).
IT 36210-76-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridinyl pyrazolo[3,4-d]pyrimidin-4-ones and pyrazolo[4,3-d]pyrimidin-7-ones as PDE 7 inhibitors)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:991360 CAPLUS
DN 140:42170
TI Preparation of arylazopyrazoles as thrombopoietin mimetics
IN Heerding, Dirk A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103686	A1	20031218	WO 2003-US17837	20030606
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003248630	A1	20031222	AU 2003-248630	20030606
	EP 1556059	A1	20050727	EP 2003-757372	20030606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006501164	T	20060112	JP 2004-510805	20030606
	US 2005234020	A1	20051020	US 2004-516988	20041206
PRAI	US 2002-386694P	P	20020606		
	US 2003-463241P	P	20030416		
	WO 2003-US17837	W	20030606		

OS MARPAT 140:42170
GI



I

AB Title compds. I [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHO, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)H(OH), heterocyclylidenemethyl; m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as thrombopoietin mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give 2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give I [R =

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 634586-08-6 CAPLUS
CN 3H-Pyrazol-3-one, 2-[3-(1,1-dimethylpropyl)cyclopentyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-Ho2CC6H4, R1-R3 = H, R4 = Me, R5 = cyclohexyl, m = 0].
IT 36210-76-1P 634585-98-1P 634585-99-2P
634586-05-3P 634586-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylazopyrazoles as thrombopoietin mimetics)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RN 634585-98-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-[cis-4-(1,1-dimethylethyl)cyclohexyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 634585-99-2 CAPLUS
CN 3H-Pyrazol-3-one, 2-[trans-4-(1,1-dimethylethyl)cyclohexyl]-2,4-dihydro-5-methyl- (CA INDEX NAME)

Relative stereochemistry.



RN 634586-05-3 CAPLUS
CN 3H-Pyrazol-3-one, 2-(3-ethylcyclopentyl)-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:777767 CAPLUS
DN 139:286349
TI Medicine for prevention and/or therapy of cardiomyopathy
IN Hayashi, Tetsuya
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080583	A1	20031002	WO 2003-JP3813	20030327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003227257	A1	20031008	AU 2003-227257	20030327
PRAI	JP 2002-87499	A	20020327		
	WO 2003-JP3813	W	20030327		

OS MARPAT 139:286349
GI



I

AB A medicine for prevention and/or therapy of cardiomyopathy, which comprises, as an active constituent, a pyrazolone derivative represented by the following formula I (R1 = H, aryl, alkyl or alkoxycarbonyl-alkyl group, and R2 = H, aryloxy, aryl-mercapto, alkyl or hydroxyalkyl group, or R1, R2 = alkylene group, and R3 = H, alkyl, cycloalkyl, hydroxyalkyl, benzyl, naphthyl, Ph group, or a Ph group substituted with the same or different one to three substituents selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, alkoxycarbonyl, alkyl-mercapto, alkylamino, dialkylamino, halogen atom, trifluoromethyl, carboxyl, cyano, hydroxyl, nitro, amino and acetamido group), or a pharmaceutically acceptable salt thereof.
IT 36210-76-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicine for prevention and/or therapy of cardiomyopathy)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:757683 CAPLUS
DN 139:261293
TI Preventive and/or therapeutic agent for hypoxic ischemic brain disorder
IN Ikeda, Tomoaki; Ikenoue, Tsuyomu
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078401	A1	20030925	WO 2003-JP3067	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005343789	A	20051215	JP 2002-71595	20020315
	AU 2003213364	A1	20030929	AU 2003-213364	20030314
PRAI	JP 2002-71595	A	20020315		
	WO 2003-JP3067	W	20030314		

OS MARPAT 139:261293
AB The patent relates to a medicine for use in the prevention of and/or treatments for hypoxic ischemic brain disorders, especially ones of newborns caused by labor. It contains as an active ingredient a substance selected from the group consisting of 3-methyl-1-phenyl-2-pyrazolin-5-one, pyralozone derivs. which are analogs thereof, physiol. acceptable salts thereof, and any hydrates and any solvates of these. Thus, 1-phenyl-3-methyl-2-pyrazolin-5-one prepared by refluxing Et acetoacetate with phenylhydrazine in ethanol and recrystn. was dissolved in simulated body fluid and showed effect on hypoxic ischemic brain of new born rat.
IT 36210-76-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrazolinone derivative for preventive and/or therapeutic agent for hypoxic ischemic brain disorder)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:704250 CAPLUS
DN 140:192190
TI Structure-activity relationship of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone)
AU Watanabe, Kazutoshi; Morinaka, Yasuhiro; Iseki, Katsuhiko; Watanabe, Toshiaki; Yuki, Satoshi; Nishi, Hiroyoshi
CS Research Laboratory I, Pharmaceuticals Research Unit, Research & Development Division, Mitsubishi Pharma Corporation, Yokohama, Japan
SO Redox Report (2003), 8(3), 151-155
CODEN: RDRPE4; ISSN: 1351-0002
PB Maney Publishing
DT Journal
LA English
OS CASREACT 140:192190
AB This paper describes the discovery of a novel free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), as a potent antioxidant agent against lipid peroxidn. The structure-activity relationship of edaravone indicated that lipophilic substituents were essential to show its lipid peroxidn.-inhibitory activity. In vivo studies revealed that edaravone showed brain-protective activity in a transient ischemia model.
IT 36210-76-1
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(preparation and structure-activity relationship of 3-Me-1-Ph-2-pyrazolin-5-one in relation to lipid peroxidn. inhibition)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:511337 CAPLUS
DN 139:85373
TI Preparation of pyrazolopyrimidinone derivatives having phosphodiesterase 7 (PDE7)-inhibitory activity
IN Inoue, Hidekazu; Murafuji, Hidenobu; Hayashi, Yasuhiro
PA Daiichi Suntory Pharma Co., Ltd., Japan; Suntory Limited; Daiichi Suntory Biomedical Research Ltd.
SO PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053975	A1	20030703	WO 2002-JP13083	20021213
	W: BR, CA, CN, HU, JP, KR, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2439784	A1	20030703	CA 2002-2439784	20021213
	BR 2002007215	A	20040210	BR 2002-7215	20021213
	EP 1454897	A1	20040908	EP 2002-788833	20021213
	EP 1454897	B1	20071010		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR, BG, CZ, EE, SK				
	CN 1533392	A	20040929	CN 2002-809154	20021213
	HU 2004002171	A2	20050228	HU 2004-2171	20021213
	AT 375347	T	20071015	AT 2002-788833	20021213
	US 2005148604	A1	20050707	US 2004-866198	20040614
	US 7268128	B2	20070911		
PRAI	JP 2001-380483	A	20011213		
	WO 2002-JP13083	W	20021213		

OS MARPAT 139:85373
GI



AB Pyrazolopyrimidinone derivs. represented by the general formula (I) or (II) [wherein A = N, CR4; wherein R4 = H, C1-3 alkoxy optionally substituted by ≥1 F atoms if necessary; B = H, halo; R1 = (un)substituted C3-7 cycloalkyl, tert-butyl; R2 = H, Me, Et; R3 = H, NO2, cyano, halo, NR5R6, C(:X)R7, SO2NR5R6, OR8, NR8COXR5R6, NR8SO2R9, heteroaryl, (un)substituted C1-3 alkyl; wherein R5, R6 = H, each (un)substituted C1-6 alkyl or acyl; or NR5R6 = azetidinyl, pyrrolidinyl, piperidinyl, morpholino, thiomorpholino, piperazinyl, or homopiperazinyl each optionally substituted by (un)substituted C1-4 alkyl, OH, C1-3 alkoxy, CO2H, or NR5R6; R7 = (un)substituted C1-6 alkyl, OH, OR8, NR5R6; R8 = H, (un)substituted C1-6 alkyl; R9 = (un)substituted C1-6 alkyl; X = O, S, NH] or salts or solvates thereof are prepared. These compds. have apprx. 10-times more potent activity for inhibiting PDE7 than PDE4, can enhance the intracellular cAMP level by virtue of their selective inhibitory activity against PDE7, and are useful in the prevention and treatment of various allergic diseases and inflammatory and immunol. diseases through their inhibiting the activation of T cells. Thus, 207

L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
μL N-methylpiperazine, 120 mg sodium tert-butoxide, 12.6 mg tri(tert-butylphosphine), and 7.0 mg Pd(OAc)2 were added to a soln. of 260 mg 6-(4-bromo-2-methoxyphenyl)-3-cyclohexyl-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one in 8 mL toluene and refluxed for 5 h to give 85% 3-cyclohexyl-6-[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (II). II.
IT 36210-76-1P 553671-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidinone derivs. as phosphodiesterase 7 (PDE7) inhibitors for prevention and treatment of various allergic diseases and inflammatory and immunol. diseases)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



RN 553671-91-3 CAPLUS
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-(4-methylcyclohexyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:138442 CAPLUS
DN 106:138442
TI Preparation of 2-pyrazoline-5-one derivatives as prophylactic and therapeutic agents for circulatory disorders
IN Nishi, Hiroyoshi; Watanabe, Toshiaki; Yuki, Satoshi; Morinaka, Yasuhiro; Iseki, Katsuhiko; Sakurai, Hiroko
PA Mitsubishi Chemical Industries Co., Ltd., Japan
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 208874	A1	19870121	EP 1986-106817	19860520
	EP 208874	B1	19900808		
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	JP 61263917	A	19861121	JP 1985-105798	19850520
	JP 05031523	B	19930512		
	JP 62108814	A	19870520	JP 1985-248057	19851107
	JP 05035128	B	19930525		
PRAI	JP 1985-105798	A	19850520		
	JP 1985-248057	A	19851107		

OS MARPAT 106:138442
GI



I

AB The title compds. I [R1 = H, aryl, alkyl, alkoxycarbonylalkyl; R2 = H, aryloxy, arylmercapto, alkyl, hydroxyalkyl; optionally R1R2 = (CH2)3-5; R3 = H, alkyl, cycloalkyl, hydroxyalkyl, benzyl, naphthyl, (substituted)phenyl], useful as prophylactic and therapeutic agents for circulating disorders, were prepared A solution of 10.8 g PhNHNH2 and 13.0 g CH3COCH2CO2Et in EtOH was refluxed to give 11.3 g I (R1 = Me, R2 = H, R3 = Ph), which as a lipid peroxidn. inhibitor had IC50 at 18.2 μM in brains of Wister-Strain male mice and antagonistic action at >1 mg/kg against drowsy pattern (in the EEG) induced by phenobarbital or pentobarbital vs. no antagonistic action in a control group. General formulations of tablets, soft capsules and injection solns. are given.
IT 36210-76-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiischemic and lipid peroxidn. inhibitor)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:143413 CAPLUS
DN 98:143413
TI 1,3-Disubstituted-5-pyrazolone derivatives
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57176963	A	19821030	JP 1981-62833	19810425
PRAI	JP 1981-62833		19810425		

GI

I

AB Title derivs. I (R, R1 = Me, Me; Me, octyl; Me, cyclohexyl; Ph, Me), useful as anticorrosives for metals (no data), were prepared by reaction of I (R1 = H) with alcs. in the presence of active halides, P compds., or SO3. Thus, 8.8 g PhSO2Cl was added to 9.8 g I (R = Me; R1 = H) in MeOH over 5 min and the mixture autoclaved 3 h at 160° to give 7.28 g I (R = R1 = Me).
IT 36210-76-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as anticorrosive agent)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1981:175114 CAPLUS
DN 94:175114
TI 1-Alkyl-3-methyl-5-pyrazolones
PA Ube Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 55108856	A	19800821	JP 1979-14997	19790214
PRAI	JP 1979-14997	A	19790214		

GI

I

AB Title compds. (I, R = Me, Bu, n-C8H17, cyclohexyl) were prepared by reaction of 3-methyl-5-pyrazolone (II) with ROH in the presence of mineral acids or 4-MeC6H4SO3H. Thus, autoclaving a mixture of N2H4.H2O 5, MeOH 160, and diketene 8.4 g 2 h at 100° yielded 9.8 g II which was heated with 6 g MeOH and 3.6 g 95 weight% H2SO4 5 h at 175° to give 5.5 g I (R = Me).
IT 36210-76-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:119941 CAPLUS
DN 76:119941
OREF 76:19371a, 19374a
TI Light-sensitive photographic material for dry copying
IN Poot, Albert L.; Van Besauw, Jan F.; Von Koenig, Anita; Kampfer, Helmut
PA Agfa-Gevaert A.-G.
SO Ger. Offen., 43 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2023629	A	19711202	DE 1970-2023629	19700514
	BE 766836	A2	19711108	BE 1971-3070	19710507
	CA 976800	A1	19751028	CA 1971-112416	19710507
	GB 1341092	A	19731219	GB 1971-14160	19710511
	US 3728115	A	19730417	US 1971-143226	19710513
	FR 2093503	A5	19720128	FR 1971-17611	19710514
PRAI	DE 1970-2023629	A	19700514		

GI For diagram(s), see printed CA Issue.
AB Dry copying is accomplished by photog. exposure of a light-sensitive composition containing a light-sensitive and a transferable image-forming compound that on exposure to light, reacts in exposed areas to form a nontransferable compound The exposed layer is contacted with an image-receiving layer containing compds. which react on heating with the image-forming compound transferred to the image-receiving layer from the nonexposed areas. The light-sensitive transferable image-forming compound is a pyrazol-5-one (I), where R1 is H, saturated or olefinic unsatd. aliphatic group, aryl, heterocyclic, or cycloalkyl, and R2 is H, saturated or olefinic unsatd. aliphatic group, aryl, heterocyclic, hydroxyl, amino or alkoxycarbonyl group, or R1 and R2 are atoms necessary to complete a carbocyclic or heterocyclic ring; R3 is H, saturated or olefinic unsatd. aliphatic group, aryl, amino, alkoxy; and R is H or 4-aminophenylamino group. The light-sensitive layer may contain as light-sensitive compound, azides, bisimidazoles and in addition, sensitizers, dyes and heavy metal compds. Thus, a solution of bis[2,2'-bis(2,4-dichlorophenyl)-4,4',5,5'-tetraphenylbiimidazole] 10 g, N-(2,5-dichlorophenyl)-3-methylpyrazolin-5-one 1 g, ethylcellulose 10 g, and 2-butanone 500 ml is coated on parchment paper and dried. A mixture containing Ag behenate 2.1, terpene resin 1.66, 1(2H)-phthalazinone 0.86, ZnO 4.8, silica gel 0.56, 2,6-di-tert-butyl-4-methylphenol 0.37, tetrachlorophthalic anhydride 0.034, 8% ethyl methacrylate solution in 3-pentanone 15, 1.5% poly(vinyl acetate) solution in BuOAc 80, and BuOAc 30 g is ballmilled for 6 hr, coated on paper and dried. The light-sensitive material is exposed to a pos. transparent original for 3 sec with a UV-radiation source of 1000-W. The exposed layer is brought in contact with the image-forming layer and heated 5 sec at 125°. A sharp, dark-black, pos. copy is obtained.
IT 36210-76-1
RL: USES (Uses)
(light-sensitive image forming compns. containing azido compds. and, for image transfer process in photoduplication)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)

L8 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1943:33746 CAPLUS
DN 37:33746
OREF 37:5422a
TI 1-Cyclohexyl-3-methyl-5-pyrazolone
PA I. G. Farbenindustrie AG
DT Patent
LA Unavailable
FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 724162		19420709	DE	

AB See Fr. 814,169 (C. A. 32, 801.3).
IT 36210-76-1P, 5-Pyrazolone, 1-cyclohexyl-3-methyl-
RL: PREP (Preparation)
(preparation of)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1939:1173 CAPLUS
DN 33:1173
OREF 33:180h-i
TI 1-Cyclohexyl-3-methyl-5-pyrazolone
IN Schuster, Curt; Krzikalla, Hans
PA General Aniline Works
DT Patent
LA Unavailable
FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2132193		19381004	US 1936-113879	19361202

AB This compound is made by treating 1-phenyl-3-methyl-5-pyrazolone in caustic alkaline solution with H at a temperature of from about 70° to 150° and at a pressure between about 100 and 250 atmospheric in the presence of hydrogenation catalysts until H is no longer absorbed. Other similar reactions are described or mentioned.
IT 36210-76-1P, 5-Pyrazolone, 1-cyclohexyl-3-methyl-
RL: PREP (Preparation)
(preparation of)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



L8 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1937:61893 CAPLUS
DN 31:61893
OREF 31:8543i,8544a-c
TI Hydrogenated compounds of several nuclei
PA I. G. Farbenindustrie A.-G.
DT Patent
LA Unavailable
FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 468375		19370701	GB 1936-54	19360101

AB Partially hydrogenated OH compds. are made by treating aromatic or heterocyclic monohydroxy compds., containing at least 2 nuclei that are joined together directly and which may contain other substituents in addition to the OH group, in alkaline solution with H under increased pressure, e. g., above 25 atmospheric, in the presence of hydrogenation catalysts, preferably at elevated temps., whereby hydrogenation takes place in the nucleus not containing the OH group. In examples, hydrogenations are conducted in the presence of a Ni-Cr catalyst, prepared by drying an aqueous mixture of NiCO3 and CrO3 and treating with N at 300° and then with H at 350°, of (1) 2,3-hydroxynaphthoic acid to its 5,6,7,8-tetrahydro derivative, (2) 2,3-hydroxynaphthoic acid anilide to its 5,6,7,8-tetrahydro derivative, and (3) 1-phenyl-3-methyl-5-pyrazolone to the corresponding 1-cyclohexyl compound The alkaline solution of 5,6,7,8-tetrahydro-2,3-hydroxynaphthoic acid anilide yields a brown dye by coupling in substance or on the fiber with diazo compds., e. g., diazotized p-nitroaniline.
IT 36210-76-1P, 5-Pyrazolone, 1-cyclohexyl-3-methyl-
RL: PREP (Preparation)
(preparation of)
RN 36210-76-1 CAPLUS
CN 3H-Pyrazol-3-one, 2-cyclohexyl-2,4-dihydro-5-methyl- (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 10:33:21 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2
DICTIONARY FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> => d que l9 stat
L9 STR



G1 NH2, NO2

Structure attributes must be viewed using STN Express query preparation.

=> d l11 1-16 ide can

L11 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 895769-55-8 REGISTRY
ED Entered STN: 25 Jul 2006
CN 2,4-Thiazolidinedione, 5-[[2-hydroxy-3-nitro-5-(phenylmethyl)phenyl]methylene]- (CA INDEX NAME)
MF C17 H12 N2 O5 S
SR Chemical Library
Supplier: Scientific Exchange, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 871085-50-6 REGISTRY
ED Entered STN: 04 Jan 2006
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitro-5-propoxyphenyl)methylene]-, (5Z)- (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H12 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:64363

L11 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 871085-47-1 REGISTRY
ED Entered STN: 04 Jan 2006
CN 2,4-Thiazolidinedione, 5-[(3-ethoxy-4-hydroxy-5-nitrophenyl)methylene]-, (5Z)- (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H10 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:64363

L11 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634585-97-0 REGISTRY
ED Entered STN: 06 Jan 2004
CN 2,4-Thiazolidinedione, 5-[(4-amino-3-hydroxyphenyl)methylene]- (CA INDEX NAME)
MF C10 H8 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L11 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634585-96-9 REGISTRY
ED Entered STN: 06 Jan 2004
CN 2,4-Thiazolidinedione, 5-[(3-hydroxy-4-nitrophenyl)methylene]- (CA INDEX NAME)
MF C10 H6 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L11 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 357154-72-4 REGISTRY
ED Entered STN: 16 Sep 2001
CN 2,4-Thiazolidinedione, 5-[(2-hydroxy-3-methoxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C11 H8 N2 O6 S
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 356798-44-2 REGISTRY
ED Entered STN: 14 Sep 2001
CN 2,4-Thiazolidinedione, 5-[(2-hydroxy-3,5-dinitrophenyl)methylene]- (CA INDEX NAME)
MF C10 H5 N3 O7 S
SR Chemical Library



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 331652-53-0 REGISTRY
ED Entered STN: 17 Apr 2001
CN 2,4-Thiazolidinedione, 5-[(3-bromo-2-hydroxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C10 H5 Br N2 O5 S
SR Chemical Library
Supplier: AsInEx
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 313659-71-1 REGISTRY
ED Entered STN: 12 Jan 2001
CN 2,4-Thiazolidinedione, 5-[(2-hydroxy-3-nitrophenyl)methylene]- (CA INDEX NAME)
MF C10 H6 N2 O5 S
SR Chemical Library
Supplier: Nanosyn Combinatorial Synthesis Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 313530-34-6 REGISTRY
ED Entered STN: 11 Jan 2001
CN 2,4-Thiazolidinedione, 5-[(3-ethoxy-2-hydroxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C12 H10 N2 O6 S
SR Chemical Library
Supplier: Nanosyn Combinatorial Synthesis Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 313238-27-6 REGISTRY
ED Entered STN: 09 Jan 2001
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-methoxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C11 H8 N2 O6 S
SR Chemical Library
Supplier: ChemDiv, Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 312926-74-2 REGISTRY
ED Entered STN: 05 Jan 2001
CN 2,4-Thiazolidinedione, 5-[(3-ethoxy-4-hydroxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C12 H10 N2 O6 S
SR Chemical Library
Supplier: Nanosyn Combinatorial Synthesis Inc.
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 301356-81-0 REGISTRY
ED Entered STN: 06 Nov 2000
CN 2,4-Thiazolidinedione, 5-[(2-hydroxy-5-nitrophenyl)methylene]- (CA INDEX NAME)
MF C10 H6 N2 O5 S
SR Chemical Library
Supplier: Otava
LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L11 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 138691-97-1 REGISTRY
ED Entered STN: 31 Jan 1992
CN 2,4-Thiazolidinedione, 5-[(3,4-dihydroxy-5-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)
MF C10 H6 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:59398

L11 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 118383-64-5 REGISTRY
ED Entered STN: 13 Jan 1989
CN 2,4-Thiazolidinedione, 5-[(3-amino-4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)
MF C10 H8 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:114893

REFERENCE 2: 114:55794

REFERENCE 3: 114:604

REFERENCE 4: 110:57657

L11 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2007 ACS on STN
RN 118383-63-4 REGISTRY
ED Entered STN: 13 Jan 1989
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)
MF C10 H6 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:114893

REFERENCE 2: 114:55794

REFERENCE 3: 114:604

REFERENCE 4: 110:57657

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 10:34:58 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 13 Nov 2007  (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l11
L12          7 L11

=> d 1-7 ibib iabs hitstr
```

L12 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1314146 CAPLUS
DOCUMENT NUMBER: 144:64363
TITLE: GPR35 and modulators thereof for the treatment of metabolic-related disorders
INVENTOR(S): Leonard, James N.; Chu, Zhi Liang; Unett, David J.; Gatlin, Joel E.; Gaidarov, Ibragim; Qiu, Jun; Skinner, Philip J.; Boatman, P. Douglas
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005119252	A2	20051215	WO 2005-US18082	20050523
WO 2005119252	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007077602	A1	20070405	US 2006-638343	20061213
PRIORITY APPLN. INFO.:			US 2004-574849P P	20040526
			US 2004-585156P P	20040701
			US 2004-612862P P	20040924
			US 2005-644684P P	20050118
			US 2005-647969P P	20050127
			WO 2005-US18082 W	20050523
			US 2006-596035 A2	20060926

OTHER SOURCE(S): MARPAT 144:64363
GRAPHIC IMAGE:



1

ABSTRACT:
The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: (a) contacting a candidate compound with GPR35, and (b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to use of a GPR35 modulator for the manufacture of a medicament for use as a metabolic stabilizing agent. In

L12 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
addn., the invention relates to a method for increasing GPR35 function, comprising contacting GPR35 with an effective amt. of a compd. of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X is O or S; and R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, C1-4 alkoxy, C1-4 alkyl, halogen, hydroxyl, and nitro; wherein said C1-4 alkoxy is optionally substituted with carbo-C1-4-alkoxy or carboxy.

IT 871085-47-1P 871085-50-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GPR35 and modulators thereof for treatment of metabolic-related disorders)
RN 871085-47-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-ethoxy-4-hydroxy-5-nitrophenyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 871085-50-6 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitro-5-propoxyphenyl)methylene]-, (5Z)- (CA INDEX NAME)

Double bond geometry as shown.



L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:991360 CAPLUS
DOCUMENT NUMBER: 140:42170
TITLE: Preparation of arylazopyrazoles as thrombopoietin mimetics
INVENTOR(S): Heerding, Dirk A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103686	A1	20031218	WO 2003-US17837	20030606
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248630	A1	20031222	AU 2003-248630	20030606
EP 1556059	A1	20050727	EP 2003-757372	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501164	T	20060112	JP 2004-510805	20030606
US 2005234020	A1	20051020	US 2004-516988	20041206
PRIORITY APPLN. INFO.:			US 2002-386694P P	20020606
			US 2003-463241P P	20030416
			WO 2003-US17837 W	20030606

OTHER SOURCE(S): MARPAT 140:42170
GRAPHIC IMAGE:



1

ABSTRACT:
Title compds. I [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHO, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)H(OH), heterocyclylidenemethyl; m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as thrombopoietin mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give 2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give I [R = 2-Ho2CC6H4, R1-R3 = H, R4 = Me, R5 =

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
cyclohexyl, m = 0].

IT 634585-96-9P 634585-97-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylazopyrazoles as thrombopoietin mimetics)
RN 634585-96-9 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-hydroxy-4-nitrophenyl)methylene]- (CA INDEX NAME)



RN 634585-97-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-amino-3-hydroxyphenyl)methylene]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:5389 CAPLUS
DOCUMENT NUMBER: 128:114893
TITLE: Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships
AUTHOR(S): Arakawa, Kenji; Inamasu, Masanori; Matsumoto, Mamoru; Okumura, Kunihito; Yasuda, Kosuke; Akatsuka, Hidenori; Kawanami, Saburo; Watanabe, Akishige; Homma, Koichi; Saiga, Yutaka; Ozeki, Masakatsu; Iijima, Ikuo
CORPORATE SOURCE: Lead Optimization Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(12), 1984-1993
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:114893
ABSTRACT:
Benzoxazole 2,4-thiazolidinediones were synthesized and evaluated for hypoglycemic activity in genetically obese and diabetic yellow KK mice. 2-Arylmethyl- and 2-(heteroarylmethyl)benzoxazole derivs. showed far more potent activity than known 2,4-thiazolidinedione derivs. such as ciglitazone, troglitazone and pioglitazone. A facile synthesis of benzoxazole 2,4-thiazolidinediones was also established using aminophenol 2,4-thiazolidinedione as a key intermediate. Details of synthesis and structure-activity relations for this series are described.

IT 118383-63-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents)
RN 118383-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)



IT 118383-64-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents)
RN 118383-64-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-amino-4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:59398 CAPLUS
DOCUMENT NUMBER: 116:59398
TITLE: Preparation of (3,4-dihydroxyphenyl)methylidenoxoazoles and -azines as medical antioxidants
INVENTOR(S): Backstrom, Reijo; Honkanen, Erkki; Linden, Inge-britt; Nissinen, Erkki; Pippuri, Aino; Pohto, Pentti; Korkolainen, Tapio
PATENT ASSIGNEE(S): Orion-Yhtyma Oy, Finland
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9117151	A1	19911114	WO 1991-FI124	19910426
W: AT, AU, CA, CH, DE, DK, ES, FI, GB, HU, KR, LU, NL, NO, PL, SE, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
ZA 9102858	A	19920129	ZA 1991-2858	19910416
CA 2080917	A1	19911028	CA 1991-2080917	19910426
CA 2080917	C	20010612		
AU 9177618	A	19911127	AU 1991-77618	19910426
AU 646464	B2	19940224		
EP 526598	A1	19930210	EP 1991-920959	19910426
EP 526598	B1	19961218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05331148	A	19931214	JP 1991-96814	19910426
JP 2972377	B2	19991108		
HU 65662	A2	19940728	HU 1992-3369	19910426
PL 166269	B1	19950428	PL 1991-296620	19910426
AT 146462	T	19970115	AT 1991-920959	19910426
RU 2096407	C1	19971120	RU 1991-92016353	19910426
RO 109841	B1	19950630	RO 1991-148578	19911015
CZ 281121	B6	19960612	CZ 1991-3130	19911015
US 5362733	A	19941108	US 1992-949477	19921023
FI 95129	B	19950915	FI 1992-4838	19921023
FI 95129	C	19951227		
NO 9204132	A	19921223	NO 1992-4132	19921026
NO 301928	B1	19971229		
LV 10097	B	19950220	LV 1992-185	19921026
HR 921248	B1	20010228	HR 1992-1248	19921112
LT 3137	B	19950131	LT 1992-227	19921117
US 5614541	A	19970325	US 1994-325024	19941018
US 5889037	A	19990330	US 1995-472658	19950607
US 6121303	A	20000919	US 1999-261460	19990223

PRIORITY APPLN. INFO.:

GB 1990-9565	A	19900427
GB 1991-1563	A	19910124
WO 1991-FI124	A	19910426
YU 1991-1392	A6	19910812
US 1992-949477	A3	19921023
US 1994-325024	A3	19941018
US 1995-472658	A1	19950607

OTHER SOURCE(S): CASREACT 116:59398; MARPAT 116:59398
GRAPHIC IMAGE:

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



ABSTRACT:
Title compds. (I; R1 = electroneg. substituent such as NO2, cyano; R2 = Q1-Q4; X1, X2, Y, Z = O, S, NR; R = H, alkyl, cycloalkyl, aralkyl, aryl), were prepared Thus, a mixture of 2-thiohydantoin, 3,4-dihydroxy-5-nitrobenzaldehyde, piperidine, and HOAc were heated at 100° for 7-8 h to give 71% title compound II. I bound peroxy radicals with stoichiometric factor = 4.0-7.1, vs 2.0 for Trolox and 0.7 for ascorbic acid.

IT 138691-97-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as medical antioxidant)
RN 138691-97-1 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3,4-dihydroxy-5-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:55794 CAPLUS
DOCUMENT NUMBER: 114:55794
TITLE: Hypolipemics containing (thiazolidinylmethyl)benzoxazoles or (thiazolidinylidenemethyl)benzoxazoles
INVENTOR(S): Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunito; Mori, Tetsuji; Inamasu, Masanori
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02167224	A	19900627	JP 1989-216742	19890822
JP 05039927	B	19930616		
WO 9119496	A1	19911226	WO 1990-JP791	19900618
W: CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
JP 05194221	A	19930803	JP 1992-257107	19920811
JP 2518497	B2	19960724		
PRIORITY APPLN. INFO.:			JP 1988-229088	A1 19880913

OTHER SOURCE(S): MARPAT 114:55794
GRAPHIC IMAGE:



I

ABSTRACT:
Hypolipemics contain title compds. I [R = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl; Alk = bond, lower alkenylene, lower alkynylene, (un)substituted lower alkylene; the dotted line may be a double bond) or their pharmacol. acceptable salts as active ingredients. Treatment of a THF-DMF solution containing 3.10 g 5-(3-amino-4-hydroxybenzyl)-2,4-dioxothiazolidine (preparation given) and N,N-dimethylaniline with a THF solution of 2.38 g 2-phenyl-4-thiazoleacetyl chloride at room temperature for 20 min gave 3.35 g N-[5-(2,4-dioxothiazolidin-5-yl)methyl-2-hydroxyphenyl]-2-phenylthiazol-4-acetamide, which was treated with trimethylsilyl polyphosphate at 100° for 30 min to afford 61% 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzoxazole (II). Rats were fed a high-cholesterol diet containing 10 mg% (sic) II for 3 days, resulting in decrease in serum cholesterol level by 30, increase in high-d. lipoprotein cholesterol level 82, and decrease in triglyceride 46%.

IT 118383-63-4P 118383-64-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of)
RN 118383-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118383-64-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-amino-4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:604 CAPLUS
DOCUMENT NUMBER: 114:604
TITLE: (Thiazolidinylmethyl)benzoxazoles or (thiazolidinylidenemethyl)benzoxazoles as hpoglycemics
INVENTOR(S): Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunito; Inamasu, Masanori
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02167225	A	19900627	JP 1989-232385	19890907
JP 05039928	B	19930616		
JP 05194222	A	19930803	JP 1992-257106	19920811
PRIORITY APPLN. INFO.:			JP 1988-233199	A1 19880916

OTHER SOURCE(S): MARPAT 114:604
GRAPHIC IMAGE:



I

ABSTRACT:
Hypoglycemics contain title compds. I [R = (un)substituted Ph, naphthyl, cycloalkyl, heterocyclyl; Alk = bond, lower alkenylene, lower alkynylene, (un)substituted lower alkylene; the dot line may be double bond] or their pharmacol. acceptable salts as active ingredients. Treatment of THF-DMF solution containing 3.10 g 5-(3-amino-4-hydroxybenzyl)-2,4-dioxothiazolidine (preparation given) and N,N-dimethylaniline with THF solution of 2.38 g 2-phenyl-4-thiazoleacetyl chloride at room temperature for 20 min gave 3.35 g N-[5-(2,4-dioxothiazolidin-5-yl)methyl-2-hydroxyphenyl]-2-phenylthiazol-4-acetamide, which was then treated with trimethylsilyl polyphosphate at 100° for 30 min to afford 61% 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-[(2-phenyl-1,3-thiazol-4-yl)methyl]benzoxazole (II). Hypoglycemic effects of II (administered in diet) were demonstrated in rats.y.

IT 118383-63-4P 118383-64-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of)
RN 118383-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118383-64-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-amino-4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:57657 CAPLUS
DOCUMENT NUMBER: 110:57657
TITLE: Preparation of 5-[benzoxazolylmethyl(or methylene)]-2,4-thiazolidinediones as antidiabetics
INVENTOR(S): Iijima, Ikuo; Ozeki, Masakatsu; Okumura, Kunihito; Inamasu, Masanori
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283035	A1	19880921	EP 1988-104361	19880318
EP 283035	B1	19911106		
R: AT, BE, CH, DE, ES, GB, GR, IT, LI, LU, NL, SE				
FI 8801103	A	19880919	FI 1988-1103	19880309
FI 91869	B	19940513		
FI 91869	C	19940825		
JP 01056675	A	19890303	JP 1988-58068	19880310
JP 05005832	B	19930125		
US 4897393	A	19900130	US 1988-167391	19880314
AU 8813177	A	19880922	AU 1988-13177	19880316
AU 600805	B2	19900823		
CA 1304371	C	19920630	CA 1988-561556	19880316
DK 8801474	A	19880919	DK 1988-1474	19880317
CN 88101542	A	19881005	CN 1988-101542	19880317
CN 1026322	B	19941026		
HU 50339	A2	19900129	HU 1988-1317	19880317
HU 204525	B	19920128		
IL 102894	A	19930221	IL 1988-102894	19880317
IL 85767	A	19930818	IL 1988-85767	19880317
FR 2612516	A1	19880923	FR 1988-3570	19880318
FR 2612516	B1	19921113		
AT 69226	T	19911115	AT 1988-104361	19880318
ES 2037752	T3	19930701	ES 1988-104361	19880318
US 4948900	A	19900814	US 1989-435807	19891113
AU 9055783	A	19901011	AU 1990-55783	19900521
AU 618483	B2	19911219		
CA 1326489	C2	19940125	CA 1991-616209	19911024

PRIORITY APPLN. INFO.:

JP 1987-65359	A	19870318
JP 1987-67073	A	19870320
US 1988-167391	A3	19880314
CA 1988-561556	A3	19880316
IL 1988-85767	A3	19880317
EP 1988-104361	A	19880318

OTHER SOURCE(S): CASREACT 110:57657; MARPAT 110:57657
GRAPHIC IMAGE: For diagram(s), see printed CA Issue.
ABSTRACT:
The title compds. [I; R = (un)substituted cycloalkyl, Ph, naphthyl, heterocyclyl; Z = bond, alkenylene, alkynylene, (un)substituted alkylene; dotted line is optional double bond] and their pharmaceutically acceptable salts were prepared as hypoglycemics, useful in treating diabetes. 4-H2NC6H4OH was converted in 3 steps to 5-(p-hydroxybenzyl)-2,4-thiazolidinedione which was nitrated and reduced to give 5-(3-amino-4-hydroxybenzyl)-2,4-thiazolidinedione. The latter was N-acylated with 2-phenyl-4-thiazoleacetyl chloride and the resulting anilide was cyclized by heating at 100° in ClCH2CH2Cl with

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
P2O5 and (Me3Si)2O to give (thiazolylmethyl)benzoxazole II. Genetically obese and diabetic mice given feed contg. 0.5 mg% II for 5 days had their blood glucose level reduced 63%.

IT 118383-63-4P 118383-64-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of hypoglycemics)
RN 118383-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-hydroxy-3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 118383-64-5 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(3-amino-4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 10:35:25 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2
DICTIONARY FILE UPDATES: 13 NOV 2007 HIGHEST RN 953361-13-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> => d que l13
L13 STR



G1 NH2, NO2
G2 H, Me, Et, n-Pr

Structure attributes must be viewed using STN Express query preparation.

=> d l15 1-5 ide can

L15 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 792905-34-1 REGISTRY
ED Entered STN: 06 Dec 2004
CN 2-Propenoic acid, 3-(4-amino-3-hydroxyphenyl)-2-methyl-, ethyl ester, (2E)- (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H15 N 03
CI COM
SR CA

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-02-0 REGISTRY
ED Entered STN: 06 Jan 2004
CN 2-Propenoic acid, 3-(4-amino-3-hydroxyphenyl)-2-methyl-, ethyl ester, hydrochloride, (2E)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H15 N 03 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (792905-34-1)

Double bond geometry as shown.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L15 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-01-9 REGISTRY
ED Entered STN: 06 Jan 2004
CN 2-Propenoic acid, 3-(3-hydroxy-4-nitrophenyl)-2-methyl-, (2E)- (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H9 N 05
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

L15 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
RN 634586-00-8 REGISTRY
ED Entered STN: 06 Jan 2004
CN 2-Propenoic acid, 3-(3-hydroxy-4-nitrophenyl)-2-methyl-, ethyl ester, (2E)- (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H13 N 05
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:42170

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 10:36:51 ON 14 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 13 Nov 2007  (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l15
L16          1 L15

=> d bib abs hitstr
```

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:991360 CAPLUS
DN 140:42170
TI Preparation of arylazopyrazoles as thrombopoietin mimetics
IN Heerding, Dirk A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003103686	A1	20031218	WO 2003-US17837	20030606
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003248630	A1	20031222	AU 2003-248630	20030606
	EP 1556059	A1	20050727	EP 2003-757372	20030606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006501164	T	20060112	JP 2004-510805	20030606
	US 2005234020	A1	20051020	US 2004-516988	20041206
PRAI	US 2002-386694P	P	20020606		
	US 2003-463241P	P	20030416		
	WO 2003-US17837	W	20030606		

OS MARPAT 140:42170
GI



I

AB Title compds. I [R-R3 = H, (un)substituted alkyl, alkenyl, aryl, OH, SH, S(O)H, SO2H, NH2, CONH2, SO2NH2, CO2H, CHO, NO2, CN, halogen, cycloalkyl, P(O)(OH)2, SO3H, P(O)H(OH), heterocyclylidenemethyl; m = 0-6; R4 = (un)substituted alkyl, aryl, OH, halogen; R5 = (un)substituted cycloalkyl] were prepared for use as thrombopoietin mimetics in treating thrombocytopenia (no data). Thus, cyclohexylhydrazine hydrochloride was treated with MeCOCH2CO2Me to give 2-cyclohexyl-5-methyl-2,4-dihydropyrazol-3-one which was treated with 3,2-H2N(HO)C6H3C6H4CO2H-2 to give I [R = 2-Ho2CC6H4, R1-R3 = H, R4 = Me, R5 = cyclohexyl, m = 0].

IT 634586-00-8P 634586-01-9P 634586-02-0P

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylazopyrazoles as thrombopoietin mimetics)

RN 634586-00-8 CAPLUS
CN 2-Propenoic acid, 3-(3-hydroxy-4-nitrophenyl)-2-methyl-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 634586-01-9 CAPLUS
CN 2-Propenoic acid, 3-(3-hydroxy-4-nitrophenyl)-2-methyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 634586-02-0 CAPLUS
CN 2-Propenoic acid, 3-(4-amino-3-hydroxyphenyl)-2-methyl-, ethyl ester, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his full

     (FILE 'HOME' ENTERED AT 10:26:06 ON 14 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:26:54 ON 14 NOV 2007
L1                STRUCTURE UPLOADED
                  D
L2              1 SEA SSS SAM L1
L3              4 SEA SSS FUL L1

     FILE 'CAPLUS' ENTERED AT 10:27:31 ON 14 NOV 2007
L4              1 SEA ABB=ON  PLU=ON  L3
                  D QUE L4 STAT
                  D BIB ABS HITSTR

     FILE 'REGISTRY' ENTERED AT 10:28:45 ON 14 NOV 2007
                  D L3 1-4 IDE CAN
L5                STRUCTURE UPLOADED
                  D
L6              0 SEA SSS SAM L5
L7              6 SEA SSS FUL L5
                  D QUE L7 STAT
                  D 1-6 IDE CAN

     FILE 'CAPLUS' ENTERED AT 10:32:03 ON 14 NOV 2007
L8             17 SEA ABB=ON  PLU=ON  L7
                  D 1-17 BIB ABS HITSTR

     FILE 'REGISTRY' ENTERED AT 10:33:21 ON 14 NOV 2007
L9                STRUCTURE UPLOADED
                  D
L10             2 SEA SSS SAM L9
L11            16 SEA SSS FUL L9
                  D QUE L9 STAT
                  D L11 1-16 IDE CAN

     FILE 'CAPLUS' ENTERED AT 10:34:58 ON 14 NOV 2007
L12             7 SEA ABB=ON  PLU=ON  L11
                  D 1-7 IBIB IABS HITSTR

     FILE 'REGISTRY' ENTERED AT 10:35:25 ON 14 NOV 2007
L13               STRUCTURE UPLOADED
                  D
L14             0 SEA SSS SAM L13
L15             4 SEA SSS FUL L13
                  D QUE L13
                  D L15 1-5 IDE CAN

     FILE 'CAPLUS' ENTERED AT 10:36:51 ON 14 NOV 2007
L16             1 SEA ABB=ON  PLU=ON  L15
                  D BIB ABS HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   13 NOV 2007  HIGHEST RN 953361-13-2
     DICTIONARY FILE UPDATES:  13 NOV 2007  HIGHEST RN 953361-13-2
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE CAPLUS

FILE COVERS 1907 - 14 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 13 Nov 2007 (20071113/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.74	895.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.78	-20.28

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:37:11 ON 14 NOV 2007